Insert text and press Enter to Search

Press Releases

You searched for
Tag: Corporate


Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair

07/07/2023

Chiesi at EPNS 2023 to confirm its commitment on alpha-mannosidosis with the projection of the movie “Rare Land” and the presentation of 4 posters

23/06/2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

05/05/2023

Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc

12/04/2023

2022 for Chiesi: The Group’s international growth continues

05/04/2023

Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting

24/02/2023

Chiesi Global Rare Diseases Announces FDA Approval of Lamzede® (velmanase alfa-tycv) for Alpha-Mannosidosis

22/02/2023

Chiesi appoints Giuseppe Accogli as new Group CEO

27/01/2023

Important recognitions for Chiesi Group from the Carbon Disclosure Project (CDP) and Cerved Rating Agency

17/01/2023

Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma

21/11/2022

Chiesi Group brings together experts to discuss care for respiratory patients and presents a new treatment option for COPD at ERS Congress

05/09/2022

First carbon minimal pMDI is on track with the goal to benefit patients and planet

27/07/2022

Chiesi tracks actions taken for a healthier, more sustainable future

14/07/2022

Chiesi Group continues to grow

31/03/2022

A new clinical framework redefines the diagnosis of COPD Exacerbations

16/12/2021